Greener Asthma Inhalers on the Horizon
In the online edition of Time magazine, an article reports that asthma inhalers containing chlorofluorocarbons (CFCs) will be illegal for production or sale as of December 31st of this year, because of known detriments of CFCs to the environment. Medical patent attorneys and innovators should look for opportunities to create greener inhalers, particularly as current options are inconvenient.
The current greener asthma inhalers require a specific cleaning procedure to prevent clogging, and they also tend to be more expensive. The CFC-free options on the market today include "GlaxoSmithKline's Ventolin HFA, Schering Plough's Proventil HFA and Ivax Corp.'s Proair HFA." These contain albuterol; another inhaler from Sepracor--their Xopenex HFA--contains a similar medication, levalbuterol.
As a medical patent attorney (or at least a patent attorney with a particular specialty and expertise in medical patents anyway), I look forward with interest to green alternatives in asthma inhalers, which are both more convenient and less costly to the consumer. Something to make us all breathe a little easier.

Medication accounts for a great majority of medical patents, though every medication has its side effects. There's no doubt medicine is saving lives and yet there are clear medical patent opportunities to minimize the risks associated with them. The main difficulty, as you in the medical community may be aware, is that medication is designed to handle a specific issue within the body. However, everything within the body is connected and the challenges in treating one area without impacting any other is significant.
Consumer interest in organic and natural products—those devoid of harmful environmental toxins—continues to escalate and broaden into more and more categories. Even in the most mainstream areas of the United States, organic products are taking up more and more shelf space, indicating the patenting opportunities for organic solutions are also on the rise.